Facial hyperpigmentation remains one of the most prevalent and challenging aesthetic concerns globally. The skincare market has evolved from outdated “whitening” concepts to the pursuit of restoring natural uniformity, transparency, and a healthy “glow”. However, traditional therapeutic options often rely on direct enzymatic inhibition or aggressive exfoliation, which can compromise the skin barrier and generate subclinical inflammation, paradoxically leading to a rebound effect in pigment production. This challenge is particularly pronounced in sensitive skin and higher phototypes. This paper presents a rationally designed, highly purified synthetic tetrapeptide (Palmitoyl Tetrapeptide-112) developed via Green Chemistry principles to act as a high-affinity competitive antagonist of the Melanocortin-1 Receptor (MC1R). By modulating MC1R signaling upstream, the peptide prevents the transcription of critical melanogenic markers. In vitro evaluations demonstrated significant downregulation of Tyrosinase (TYR), Tyrosinase-related protein 1 (TYRP-1), RAB27A, and the inflammatory mediator Endothelin-1 (EDN1). Ex vivo tissue analysis confirmed a marked decrease in epidermal melanin deposition and a significant increase in dermal Type I Collagen synthesis. Furthermore, an in vivo clinical trial focusing on an Asian population with Fitzpatrick phototypes IV-V demonstrated significant reductions in both the Melanin Index and Erythema Index over 84 days, specifically within hyperpigmented areas of subjects with sensitive skin. The findings propose a multifocal, safe strategy for correcting resistant hyperchromia by breaking the continuous crosstalk between inflammation and pigmentation.